Clinical Trial

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Name: Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. — clinical trial record (NCT06885840)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multi-center, open-label, phase II clinical study of MCLA-129 as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with actionable gene alterations and MET amplification to evaluate the efficacy, safety, pharmacokinetic characteristics of MCLA-129.

Trial Details

NCT Number	NCT06885840
Lead Sponsor	Betta Pharmaceuticals Co., Ltd.
Conditions	Non-Small Cell Lung Cancer
Enrollment	100 participants
Start Date	2025-03-31
Primary Completion	2028-04 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2025-03-20